Bio & Science

Soaring popularity of obesity drugs drives sharp decline in restaurant spending Small-portion meals launched to target appetite-suppressed consumers Sales of products aimed at preventing side effects such as hair loss also climb

The Iran war has made fossil fuel dependence a direct economic risk for Asia Renewable energy competition is now central to growth, inflation control and energy security China will gain, but India can compete too

Japan’s hydrogen strategy is not just climate policy; it is a sovereignty bet Solar is cheaper today, but Japan fears dependence on China-led clean-tech supply chains The real task is to expand renewables while keeping hydrogen only for sectors where it can truly cut emissions

$11.75 Billion Organon Deal Marks Largest Acquisition in Indian Pharmaceutical History Preparing for a ‘Biosimilar Golden Age’ Amid Intensifying Global Competition More Personnel, More Clinical Trials and Streamlined Reviews Pose Threat to Korean Biotech

Aviation emissions are also a route-efficiency problem, not only a fuel problem Liberalisation can cut emissions per passenger, but it can increase total demand The best policy combines open routes with strict carbon rules

Beaten Back by Mounjaro, Wegovy Bets on an OpenAI Alliance Roche and Eli Lilly Bring Nvidia Supercomputers Online AI Upends the Drug Industry as Bio-AI Convergence Accelerates Global pharmaceutical companies are accelerating “AI alliances” th

The EU carbon border tax works like a green trade barrier for many non-EU firms It may help EU producers now, but that edge will not last Without technology transfer, it risks becoming protectionism, not fair climate policy

China’s energy rise is now a story of renewable energy security, not only emissions Its real advantage is not just hardware, but the education and training system behind it Countries that teach energy skills well will be less exposed to future oil and power shocks

Semaglutide patents expire in China and India A stream of generic drugs priced at one-eighth of the list price stands ready Broader access to obesity drugs begins in earnest Wegovy/Photo=Novo Nordisk

Supply chain risk goes far beyond rare earths Hormuz now matters for tech inputs, not just energy Resilience needs diversification and better risk mapping In 2024, the Strait of Hormuz facilitated over one-quarter of global sea

Japan proves China dependence is hard to replace, even after years of effort The real task is de-risking, not full decoupling That means coordination, processing capacity, and skilled labor Fifteen years after

Round Two of the Global Obesity Drug Boom Convenience-Driven Shift Toward Oral Therapies Competition to Capture the $150 Billion Market Intensifies The paradigm of the obesity treatment market

Cortical Labs to build commercial data centers in Australia and Singapore using ‘CL1’ Bio-computing emerges as an alternative to AI-driven power shortages, demonstrating potential for intelligent information processing Experts caution the technology remains in an early stage despite intensifying development race

As the patent expiration of semaglutide nears in China, will price competition begin in earnest The biopharmaceutical industry is also accelerating development of new drugs to rival Wegovy Competition is expanding to secure next-generation obesity treatments such as oral drugs

Solar subsidies helped drive the dramatic fall in solar energy costs But geography determines who benefits most from cheap solar Smart policy must match solar expansion with regional cooperation and grid investment Solar subsidies h

Sodium-ion batteries promise cheaper, safer energy storage The technology still needs large-scale testing and validation Targeted deployment could reshape clean energy systems The rise of sodium-ion batteries could be a tran

China’s rare earth dominance comes mainly from processing technology Supply disruptions often trigger innovation elsewhere Critical minerals cooperation is key for resilient supply chains In 2024, data indicate that Ch

Aging and migration strain universal healthcare budgets Exclusion is not sustainable Smart funding reform can protect equity and stability Europe’s public health budgets face a simple arithmetic squeeze: current

Beijing Steps Up Support for BCI Sector, Driving Surge in Clinical Trials and Investment Industry Frontrunner Neuralink Accelerates Mass Production and Portfolio Expansion FDA Regulatory Overhang Weighs on Neuralink, Raising Commercialization Barriers

Appetite is not a single switch but a network that can now be powerfully overridden Multi-pathway obesity drugs deliver record weight loss while introducing new biological risks Policy and education must adapt as fast as the science does